BEAM THERAPEUTICS INC

NASDAQ: BEAM (Beam Therapeutics Inc.)

最近更新时间: 13 Nov, 2024, 2:20PM

27.36

-0.58 (-2.08%)

前收盘价格 27.94
收盘价格 28.22
成交量 430,191
平均成交量 (3个月) 909,748
市值 2,265,561,344
价格/销量 (P/S) 6.18
股市价格/股市净资产 (P/B) 2.76
52周波幅
20.84 (-23%) — 49.50 (80%)
营业毛利率 -41.07%
营业利益率 (TTM) -746.40%
稀释每股收益 (EPS TTM) -1.58
季度收入增长率 (YOY) -17.00%
总债务/股东权益 (D/E MRQ) 20.48%
流动比率 (MRQ) 5.69
营业现金流 (OCF TTM) -135.81 M
杠杆自由现金流 (LFCF TTM) -38.55 M
资产报酬率 (ROA TTM) -9.27%
股东权益报酬率 (ROE TTM) -18.29%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Beam Therapeutics Inc. 看跌 看跌

AIStockmoo 评分

-0.8
分析师共识 -0.5
内部交易活动 0.0
价格波动 2.0
技术平均移动指标 -3.5
技术振荡指标 -2.0
平均 -0.80

相关股票

股票 市值 DY P/E(TTM) P/B
BEAM 2 B - - 2.76
VIR 2 B - - 1.17
FTRE 2 B - - 1.08
SYRE 1 B - - 7.32
SPRY 1 B - - 5.10
NTLA 1 B - - 1.08

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

部门 Healthcare
行业 Biotechnology
投资方式 Small Value
内部持股比例 1.48%
机构持股比例 93.10%

所有权

姓名 日期 持有股份
Mwg Management Ltd. 30 Sep 2024 2,266,934
52周波幅
20.84 (-23%) — 49.50 (80%)
目标价格波幅
24.00 (-12%) — 80.00 (192%)
80.00 (HC Wainwright & Co., 192.40%) 购买
31.50 (15.13%)
24.00 (RBC Capital, -12.28%) 保留
24.00 (Scotiabank, -12.28%) 保留
平均值 41.75 (52.60%)
总计 2 购买, 2 保留
平均价格@调整类型 26.86
公司 日期 目标价格 调整类型 价格@调整类型
HC Wainwright & Co. 09 Dec 2024 80.00 (192.40%) 购买 27.52
07 Nov 2024 80.00 (192.40%) 购买 26.10
Leerink Partners 06 Nov 2024 39.00 (42.54%) 购买 26.62
RBC Capital 06 Nov 2024 24.00 (-12.28%) 保留 26.62
Scotiabank 16 Oct 2024 24.00 (-12.28%) 保留 26.69
名称 平均购买 ($) 平均卖出 ($) 总净额 总净值 ($)
BELLON CHRISTINE - 24.70 -1,241 -30,653
CAVANAGH BETHANY J - 24.70 -1,117 -27,590
累积净数量 -2,358
累积净值 ($) -58,243
累积平均购买 ($) -
累积平均卖出 ($) 24.70
名称 持有人 日期 类型 数量 价格 价值 ($)
CAVANAGH BETHANY J 职员 02 Jan 2025 自动卖出 (-) 1,117 24.70 27,590
BELLON CHRISTINE 职员 02 Jan 2025 自动卖出 (-) 1,241 24.70 30,653
日期 类型 细节
13 Jan 2025 公告 Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
17 Dec 2024 公告 Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08 Dec 2024 公告 Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
07 Dec 2024 公告 Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
06 Dec 2024 公告 Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
04 Dec 2024 公告 Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
12 Nov 2024 公告 Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
05 Nov 2024 公告 Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
05 Nov 2024 公告 Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
29 Oct 2024 公告 Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票